Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2019; 25(43): 6440-6450
Published online Nov 21, 2019. doi: 10.3748/wjg.v25.i43.6440
Serum amyloid A levels in patients with liver diseases
Zi-Ying Yuan, Xing-Xin Zhang, Yu-Jing Wu, Zhi-Ping Zeng, Wei-Min She, Shi-Yao Chen, Yuan-Qing Zhang, Jin-Sheng Guo
Zi-Ying Yuan, Xing-Xin Zhang, Yu-Jing Wu, Zhi-Ping Zeng, Wei-Min She, Shi-Yao Chen, Jin-Sheng Guo, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Zi-Ying Yuan, Xing-Xin Zhang, Yu-Jing Wu, Zhi-Ping Zeng, Wei-Min She, Shi-Yao Chen, Jin-Sheng Guo, Shanghai Institute of Liver Diseases, Shanghai 200032, China
Zi-Ying Yuan, Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
Yuan-Qing Zhang, The First Affiliated Hospital, Yunnan Institute of Digestive Disease, Kunming Medical University, Kunming 650000, Yunnan Province, China
Author contributions: Guo JS designed the research; Yuan ZY and Zhang XX performed the research; Wu YJ, Zeng ZP, She WM, and Zhang YQ contributed to data collection; Yuan ZY, Zhang XX and Chen SY analyzed the data; Yuan ZY and Guo JS wrote the paper.
Supported by the National Natural Science Foundation of China, No. 91129705, No. 81070340, and No. 30570825; and Science and Technology Commission of Shanghai Municipality, Shanghai Pujiang Talent Program, No. 09PJ1402600.
Institutional review board statement: This research was approved by Ethics Committee of Zhongshan Hospital Affiliated to Fudan University.
Informed consent statement: Informed consent was obtained from all subjects.
Conflict-of-interest statement: All authors declare that they have no conflicts of interest to disclose.
Data sharing statement: Data are available from the corresponding author at guo.jinsheng@zs-hospital.sh.cn.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jin-Sheng Guo, MD, PhD, Chief Physician of Medicine, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai Institute of Liver Diseases, 180 Fenglin Road, Shanghai 200032, China. guo.jinsheng@zs-hospital.sh.cn
Telephone: +86-21-64041990-2424 Fax: +86-21-64038472
Received: June 24, 2019
Peer-review started: June 26, 2019
First decision: August 28, 2019
Revised: September 23, 2019
Accepted: November 7, 2019
Article in press: November 7, 2019
Published online: November 21, 2019
Processing time: 151 Days and 23.1 Hours
Core Tip

Core tip: Serum amyloid A (SAA) is an acute phase protein known to have diagnostic and prognostic value in many diseases. However, the SAA level and its clinical significance in various liver diseases have not been reported. Our study found that serum level of SAA is a sensitive biomarker for inflammatory activity of pyogenic liver abscess, and to a less extent, to reflect mild inflammatory status in autoimmune liver diseases, drug-induced liver injury, chronic active hepatitis B, and nonalcoholic steatohepatitis. Serum level of SAA can be confounded by various inflammatory diseases, thus it is not a specific indicator for certain diseases.